Journal of the American College of Cardiology最新文献

筛选
英文 中文
Percutaneous Left Atrial Appendage Closure Device Utilization Among Medicare Beneficiaries. 经皮左心耳封闭装置在医疗保险受益人中的应用。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-12 DOI: 10.1016/j.jacc.2026.07.040
Peter G Brodeur, Jason Nelson, Yang Song, Enrico G Ferro, Robert W Yeh, Rishi K Wadhera, Daniel B Kramer
{"title":"Percutaneous Left Atrial Appendage Closure Device Utilization Among Medicare Beneficiaries.","authors":"Peter G Brodeur, Jason Nelson, Yang Song, Enrico G Ferro, Robert W Yeh, Rishi K Wadhera, Daniel B Kramer","doi":"10.1016/j.jacc.2026.07.040","DOIUrl":"https://doi.org/10.1016/j.jacc.2026.07.040","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation: Navigating Heterogeneity in Clinical Evidence: JACC Evidence Review. 左心房附件关闭或抗凝治疗心房颤动:导航临床证据的异质性:JACC证据回顾。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-12 DOI: 10.1016/j.jacc.2026.09.018
Behnood Bikdeli, Adith S Arun, Shubhadarshini Pawar, Sanket S Dhruva, Neel M Butala, Celina Yong, Erica S Spatz, David J Cohen, John A Bittl, Christine M Albert, Martin B Leon, Raj R Makkar, Saman Nazarian, Harlan M Krumholz, Aakriti Gupta
{"title":"Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation: Navigating Heterogeneity in Clinical Evidence: JACC Evidence Review.","authors":"Behnood Bikdeli, Adith S Arun, Shubhadarshini Pawar, Sanket S Dhruva, Neel M Butala, Celina Yong, Erica S Spatz, David J Cohen, John A Bittl, Christine M Albert, Martin B Leon, Raj R Makkar, Saman Nazarian, Harlan M Krumholz, Aakriti Gupta","doi":"10.1016/j.jacc.2026.09.018","DOIUrl":"https://doi.org/10.1016/j.jacc.2026.09.018","url":null,"abstract":"<p><p>Left atrial appendage closure (LAAC) has emerged as an alternative to long-term anticoagulation for preventing stroke or systemic embolism in selected patients with atrial fibrillation (AF) based on several randomized controlled trials (RCTs) that collectively enrolled >7,000 participants. In this JACC Evidence Review, we interpret the major RCTs as distinct experiments, clarify what each can and cannot establish, and offer a phenotype-based framework for interpreting the evidence. The most recent RCTs, OPTION, CLOSURE-AF, and CHAMPION-AF, have prompted efforts to pool the evidence into a single summary estimate. However, these trials are not one coherent evidence base; they are distinct clinical experiments that asked different questions. They differ in patient phenotype, comparator, device generation, postprocedure antithrombotic regimen, endpoint construction, and follow-up duration. Study-level meta-analysis of published reports remains methodologically valid for estimating the broad direction of effect of a device class, but when the component trials differ materially in patient phenotype, comparator, and outcome construction, the pooled estimate does not map to a common patient group or treatment decision. Patient eligibility as well as thromboembolic and bleeding risk varied markedly across trials. In addition, device technology has progressed, and comparators have evolved from warfarin to direct oral anticoagulants. Heterogeneity and insufficient details also exist about the antithrombotic therapy regimen in LAAC arms and adjunct antiplatelet therapy in control arms. Methodological issues further complicate interpretation, including the use of bleeding events (ie, the putative ancillary benefit of LAAC compared with anticoagulation) within composite endpoints tested for noninferiority, varying noninferiority margins, analytical approaches that may undermine the interpretation of noninferiority, and exclusion of periprocedural bleeding from primary safety endpoints in some trials. Finally, the standard of care for anticoagulation in AF has evolved, obviating concomitant aspirin use in stable individuals on therapeutic anticoagulation, thereby reducing bleeding risk compared with that of the control arm of LAAC RCTs. For most anticoagulation-eligible patients, anticoagulation remains the preferred first-line strategy. LAAC is a reasonable option when long-term anticoagulation is unsafe or unsustainable provided that procedural risk, adjunct antithrombotic feasibility, surveillance needs, and competing mortality are carefully considered. RCT evidence in this latter population is limited, and RCTs in other populations have features that limit their support for LAAC as an alternative to anticoagulation. Because LAAC and anticoagulation offer different types of risk, aligning the most applicable evidence with patient values through shared decision-making is central to care.</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":""},"PeriodicalIF":22.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: The NOTION-4 Trial. 经导管主动脉瓣短期抗凝治疗和亚临床小叶增厚:notion4试验。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-10 Epub Date: 2026-08-30 DOI: 10.1016/j.jacc.2026.08.023
Troels Højsgaard Jørgensen, Andreas Fuchs Larsen, Jesper Møller Jensen, Rebekka Vibjerg Jensen, Yannick Willemen, Aekapat Phoksiri, Arif Khokhar, Jani Thuraiaiyah, Kamilla Bech Pedersen, Gintautas Bieliauskas, Christian Juhl Terkelsen, Lars Søndergaard, Klaus Fuglsang Kofoed, Bjarne Linde Nørgaard, Ole De Backer
{"title":"Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: The NOTION-4 Trial.","authors":"Troels Højsgaard Jørgensen, Andreas Fuchs Larsen, Jesper Møller Jensen, Rebekka Vibjerg Jensen, Yannick Willemen, Aekapat Phoksiri, Arif Khokhar, Jani Thuraiaiyah, Kamilla Bech Pedersen, Gintautas Bieliauskas, Christian Juhl Terkelsen, Lars Søndergaard, Klaus Fuglsang Kofoed, Bjarne Linde Nørgaard, Ole De Backer","doi":"10.1016/j.jacc.2026.08.023","DOIUrl":"10.1016/j.jacc.2026.08.023","url":null,"abstract":"<p><strong>Background: </strong>Following transcatheter aortic valve replacement (TAVR), subclinical leaflet thrombosis-visualized on cardiac computed tomography (CT) as hypoattenuated leaflet thickening (HALT)-is common and might be associated with thromboembolic events.</p><p><strong>Objectives: </strong>The NOTION-4 trial investigates different antithrombotic treatment strategies for the prevention of HALT.</p><p><strong>Methods: </strong>NOTION-4 was a randomized controlled trial enrolling patients without an indication for oral anticoagulation shortly after successful TAVR. Patients were randomized to lifelong single antiplatelet therapy (SAPT) or 3 months of direct oral anticoagulant (DOAC) therapy followed by lifelong SAPT (DOAC-3m). The primary endpoint was HALT prevalence at 12 months. The trial was powered for superiority of the experimental strategy.</p><p><strong>Results: </strong>Of 352 patients randomized 1:1, 5 were screen failures or withdrew consent, leaving 176 in the SAPT group and 171 in the DOAC-3m group. At 3 months, HALT was observed in 31.8% of patients receiving SAPT compared with 12.1% of those receiving DOAC-3m. At 1 year, HALT occurred in 32.2% of SAPT patients and 28.3% of DOAC-3m patients with available CT scans (risk difference: -3.9%; 95% CI: -14.4% to 6.6%; P = 0.54). The combined risk of all-cause mortality, stroke, or major/life-threatening bleeding at 12 months was 2.3% in the SAPT group vs 8.2% in the DOAC-3m group (risk difference: 5.9%; 95% CI: 1.2% to 10.6%).</p><p><strong>Conclusions: </strong>Among TAVR patients without an indication for oral anticoagulation, 3 months of DOAC therapy significantly reduced the prevalence of HALT at 3 months compared with SAPT; however, this effect was attenuated by 9 months after discontinuation of DOAC therapy. (The Nordic Aortic Valve Intervention Trial 4 [NOTION-4]; NCT06449469).</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"2187-2197"},"PeriodicalIF":22.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Still Searching: The Paradox of Low-Flow, Low-Gradient Severe Aortic Stenosis. 仍在探索:低流量,低梯度严重主动脉瓣狭窄的悖论。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-10 Epub Date: 2026-10-07 DOI: 10.1016/j.jacc.2026.08.049
Patricia A Pellikka
{"title":"Still Searching: The Paradox of Low-Flow, Low-Gradient Severe Aortic Stenosis.","authors":"Patricia A Pellikka","doi":"10.1016/j.jacc.2026.08.049","DOIUrl":"10.1016/j.jacc.2026.08.049","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"2184-2186"},"PeriodicalIF":22.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Right Heart Dysfunction in Valvular Heart Disease: Epidemiology, Prognosis, and Management Considerations. 瓣膜性心脏病右心功能障碍:流行病学、预后和管理考虑。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-10 DOI: 10.1016/j.jacc.2026.08.035
Michael I Brener, Luigi P Badano, Xavier Galloo, Denisa Muraru, Sean P Pinney, Vallerie V McLaughlin, Jörg Hausleiter, Philip Lurz, Robin Le Ruz, Nicolas M van Mieghem, Ludwig T Weckbach, Gorav Ailawadi, Fabien Praz, Brian R Lindman, Arash Salavitabar, Omar Chehab, Thomas J Stocker, Joann Lindenfeld, Martin B Leon, Daniel Burkhoff, Rebecca T Hahn
{"title":"Right Heart Dysfunction in Valvular Heart Disease: Epidemiology, Prognosis, and Management Considerations.","authors":"Michael I Brener, Luigi P Badano, Xavier Galloo, Denisa Muraru, Sean P Pinney, Vallerie V McLaughlin, Jörg Hausleiter, Philip Lurz, Robin Le Ruz, Nicolas M van Mieghem, Ludwig T Weckbach, Gorav Ailawadi, Fabien Praz, Brian R Lindman, Arash Salavitabar, Omar Chehab, Thomas J Stocker, Joann Lindenfeld, Martin B Leon, Daniel Burkhoff, Rebecca T Hahn","doi":"10.1016/j.jacc.2026.08.035","DOIUrl":"https://doi.org/10.1016/j.jacc.2026.08.035","url":null,"abstract":"<p><p>Right ventricular (RV) dysfunction is an important determinant of clinical outcomes across a wide range of cardiovascular pathologies. As the prevalence of valvular heart disease (VHD) increases with the aging population, the intersection between RV function and VHD will become all the more relevant for proper risk assessment, treatment selection, and prognostication. Even though RV dysfunction may not always be attributed to VHD, we aim to give clinicians, researchers, and regulators a deep understanding of how patients with VHD should be evaluated for RV dysfunction and treated when RV dysfunction coexists with VHD. We begin with a discussion of the epidemiology and diagnostic evaluation of RV dysfunction in patients with a variety of VHD subgroups, including right-side (ie, associated with the tricuspid valve) and left-side (ie, associated with the mitral and aortic valves) VHD. Attention is also given in that section to contemporary methods and evolving techniques for identifying and phenotyping different forms of RV dysfunction in patients with VHD. No single imaging test practically or comprehensively captures all degrees and forms of RV dysfunction in patients with VHD; therefore, the discussion emphasizes integrating evidence from different imaging modalities and hemodynamic assessments. The second component of the review discusses how RV dysfunction affects therapeutic options, including medical, transcatheter, and surgical therapies for VHD. The focus of the discussion is on the interplay between RV dysfunction in patients with right-side VHD, namely tricuspid regurgitation (TR). Unlike left-side VHD, where RV dysfunction is a marker of overall disease severity but does not necessarily indicate futility or nonresponse to therapy, right-side VHD and TR-associated RV dysfunction identifies a subset of patients where intervention may precipitate even worse RV function. The nuances of these interactions between ventricular and valvular function are the emphasis of this section, and we aim to provide a framework for understanding RV function in the context of these different forms of VHD. Finally, the review concludes with an eye to the future, discussing the ways in which RV dysfunction can be identified and managed with the use of novel techniques. This discussion is increasingly relevant as RV dysfunction and VHD frequently coexist, and accurate identification is critical to matching the right treatment for the right patient.</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"88 19","pages":"2221-2243"},"PeriodicalIF":22.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcatheter Aortic Valve Replacement or Medical Treatment for Paradoxical Low-Flow, Low-Gradient Aortic Valve Stenosis: REBOOT-PARADOX. 经导管主动脉瓣置换术或药物治疗悖论低流量,低梯度主动脉瓣狭窄:重启悖论。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-10 Epub Date: 2026-08-28 DOI: 10.1016/j.jacc.2026.08.017
Julinda Mehilli, Julius Steffen, Tanja Rudolph, Magda Haum, Christina Giannini, Konstantin Stark, Hüseyin Ince, Lenard Conradi, Michael Joner, Andreas Schäfer, Ann-Katrin Karcher, Martin Landt, Matti Adam, Holger Thiele, Tobias Geisler, David Jochheim, Christian Hagl, Uwe Zeymer, Stephan Windecker, Steffen Massberg
{"title":"Transcatheter Aortic Valve Replacement or Medical Treatment for Paradoxical Low-Flow, Low-Gradient Aortic Valve Stenosis: REBOOT-PARADOX.","authors":"Julinda Mehilli, Julius Steffen, Tanja Rudolph, Magda Haum, Christina Giannini, Konstantin Stark, Hüseyin Ince, Lenard Conradi, Michael Joner, Andreas Schäfer, Ann-Katrin Karcher, Martin Landt, Matti Adam, Holger Thiele, Tobias Geisler, David Jochheim, Christian Hagl, Uwe Zeymer, Stephan Windecker, Steffen Massberg","doi":"10.1016/j.jacc.2026.08.017","DOIUrl":"10.1016/j.jacc.2026.08.017","url":null,"abstract":"<p><strong>Background: </strong>Paradoxical low-flow, low-gradient (pLFLG) aortic stenosis (AS) has an adverse prognosis in comparison to other AS subtypes. Transcatheter aortic valve replacement (TAVR) has never been compared with optimal medical therapy (OMT) alone in a dedicated randomized trial in this population.</p><p><strong>Objectives: </strong>The trial sought to determine whether TAVR added to OMT reduces all-cause mortality in symptomatic patients with pLFLG AS.</p><p><strong>Methods: </strong>In this multicenter, open-label trial, patients with symptomatic pLFLG AS (aortic valve area ≤1.0 cm<sup>2</sup>, mean gradient <40 mm Hg, stroke volume index <35 mL/m<sup>2</sup>, ejection fraction ≥50%) were randomly assigned 2:1 to TAVR plus OMT or OMT alone. The primary endpoint was all-cause death, assessed 2 years after enrollment of the last patient. Enrollment was stopped prematurely for slow recruitment.</p><p><strong>Results: </strong>Of 783 planned patients, 120 (median age 82 years; 53.3% women) were randomized (80 TAVR, 40 OMT). A total of 19 OMT patients eventually crossed over to TAVR, most for symptom progression. The primary endpoint occurred in 29.0% vs 37.1% (HR: 0.83; 95% CI: 0.41-1.66; P = 0.60), and 5-year mortality was 44.9% vs 56.6% (HR: 0.76; 95% CI: 0.43-1.35; P = 0.35). TAVR was associated with improved symptoms (NYHA functional class I/II at 1 year, 83.0% vs 59.0%) and lower cumulative incidence of first endpoint-related rehospitalizations, and there were no differences in functional capacity or quality of life.</p><p><strong>Conclusions: </strong>Although the effect of TAVR on mortality remains unresolved, these findings support an individualized strategy with close surveillance and timely TAVR upon clinical deterioration in selected patients with pLFLG AS. Adequately powered randomized trials are needed to define the effect of early TAVR on prognosis. (accuRate Evaluation of Benefit with Optimal medical treatment with or withOut Transcatheter valve repair of PARADOXical low flow low gradient aortic stenosis [REBOOT-PARADOX Trial]; NCT03863132).</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"2168-2183"},"PeriodicalIF":22.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transseptal Transcatheter Mitral Valve Replacement for Mitral Annular Calcification: ENCIRCLE MAC Registry 1-Year Outcomes. 经房间隔经导管二尖瓣置换术治疗二尖瓣环钙化:环MAC注册1年结果。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-10 Epub Date: 2026-10-14 DOI: 10.1016/j.jacc.2026.08.016
Mayra E Guerrero, David V Daniels, Brian Whisenant, Raj R Makkar, Pradeep Yadav, Vinod Thourani, Amar Krishnaswamy, Kamran I Muhammad, Michael Morse, Evelio Rodriguez, Adam B Greenbaum, Charanjit Rihal, Christine Chung, Alejandro Vasquez, Nicolas van Mieghem, Paul Sorajja, Philip Gideon, Thom G Dahle, Jason Foerst, J Bradley Oldemeyer, Neil Fam, Curtiss Stinis, Matthew J Price, Oluseun Alli, Daniel Pu, Brian P O'Neill, Dale Murdoch, John Wang, Philipp Blanke, Michael Pham, Federico M Asch, John Webb
{"title":"Transseptal Transcatheter Mitral Valve Replacement for Mitral Annular Calcification: ENCIRCLE MAC Registry 1-Year Outcomes.","authors":"Mayra E Guerrero, David V Daniels, Brian Whisenant, Raj R Makkar, Pradeep Yadav, Vinod Thourani, Amar Krishnaswamy, Kamran I Muhammad, Michael Morse, Evelio Rodriguez, Adam B Greenbaum, Charanjit Rihal, Christine Chung, Alejandro Vasquez, Nicolas van Mieghem, Paul Sorajja, Philip Gideon, Thom G Dahle, Jason Foerst, J Bradley Oldemeyer, Neil Fam, Curtiss Stinis, Matthew J Price, Oluseun Alli, Daniel Pu, Brian P O'Neill, Dale Murdoch, John Wang, Philipp Blanke, Michael Pham, Federico M Asch, John Webb","doi":"10.1016/j.jacc.2026.08.016","DOIUrl":"10.1016/j.jacc.2026.08.016","url":null,"abstract":"<p><strong>Background: </strong>Patients with symptomatic mitral valve dysfunction (MVD) and mitral annular calcification (MAC) represent one of the most challenging populations in structural heart disease. Advanced age, multiple comorbidities, extensive annular calcification, and unfavorable anatomy often preclude surgical mitral valve replacement or transcatheter repair, leaving many patients with limited treatment options. Whether fully percutaneous transseptal transcatheter mitral valve replacement (TMVR) can provide a meaningful treatment pathway for patients with MAC-related MVD remains uncertain.</p><p><strong>Objectives: </strong>The goal of this study was to evaluate 1-year clinical, echocardiographic, and patient-centered outcomes after transseptal TMVR with the SAPIEN M3 system in patients with symptomatic MAC-related MVD.</p><p><strong>Methods: </strong>The ENCIRCLE (SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access) trial MAC Registry is a prospective, multicenter, single-arm study that enrolled symptomatic patients with MAC-related MVD, including ≥ moderate to severe mitral regurgitation (MR), severe mitral stenosis, or combined moderate MR with at least moderate mitral stenosis, who were considered unsuitable for surgery or transcatheter repair. The primary endpoint was a nonhierarchical composite of all-cause mortality and heart failure hospitalization (HFH) at 1 year.</p><p><strong>Results: </strong>Among 364 screened patients, TVMR was attempted in 100, and the valve was implanted in 93. Mean age was 76.1 ± 9.2 years, 51.0% were male, 73.0% were in NYHA functional class III/IV, and mean Society of Thoracic Surgeons Predicted Risk of Mortality score for mitral valve replacement was 8.4% ± 4.9%. At 1 year, the Kaplan-Meier estimate of all-cause mortality or HFH was 33.6% (95% CI: 25.0%-44.1%), with 21.1% all-cause mortality and 19.4% HFH. Disabling stroke occurred in 5.1%, clinically significant left ventricular outflow tract obstruction in 4.8%, valve thrombosis in 2.3%, hemolysis requiring transfusion or mitral valve reintervention in 9.2%, and mitral valve re-intervention in 11.4%. Among implanted patients, MR ≤1+ was achieved in 98.5% at 1 year. Improvements in NYHA functional class, Kansas City Cardiomyopathy Questionnaire Overall Summary score, and 6-minute walk distance were sustained through 1 year.</p><p><strong>Conclusions: </strong>In carefully selected patients with symptomatic MAC-related MVD unsuitable for surgery or transcatheter repair, transseptal TMVR with the SAPIEN M3 system was associated with sustained MR reduction and meaningful improvements in symptoms and quality of life through 1 year. These findings support consideration of transseptal TMVR as a treatment pathway for selected patients with MAC-related MVD.</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"2202-2216"},"PeriodicalIF":22.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coming Full Circle in Transcatheter Mitral Valve Intervention in MAC: Lessons From the ENCIRCLE Registry. MAC经导管二尖瓣介入治疗的完整循环:来自ENCIRCLE注册表的经验。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-10 Epub Date: 2026-10-14 DOI: 10.1016/j.jacc.2026.08.041
Lucy M Safi, Sahil Khera, Gilbert H L Tang
{"title":"Coming Full Circle in Transcatheter Mitral Valve Intervention in MAC: Lessons From the ENCIRCLE Registry.","authors":"Lucy M Safi, Sahil Khera, Gilbert H L Tang","doi":"10.1016/j.jacc.2026.08.041","DOIUrl":"10.1016/j.jacc.2026.08.041","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"2217-2220"},"PeriodicalIF":22.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Race, Risk, and What the Model Is For. 种族、风险和模型的用途。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-10 DOI: 10.1016/j.jacc.2026.10.003
Harlan M Krumholz
{"title":"Race, Risk, and What the Model Is For.","authors":"Harlan M Krumholz","doi":"10.1016/j.jacc.2026.10.003","DOIUrl":"https://doi.org/10.1016/j.jacc.2026.10.003","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"88 19","pages":"2165-2167"},"PeriodicalIF":22.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When Leaflet Thickening Becomes More Than an Imaging Finding. 当小叶增厚不仅仅是一种影像学表现。
IF 22.3 1区 医学
Journal of the American College of Cardiology Pub Date : 2026-11-10 DOI: 10.1016/j.jacc.2026.09.1832
Aakriti Gupta, Hasan Jilaihawi, Raj R Makkar
{"title":"When Leaflet Thickening Becomes More Than an Imaging Finding.","authors":"Aakriti Gupta, Hasan Jilaihawi, Raj R Makkar","doi":"10.1016/j.jacc.2026.09.1832","DOIUrl":"https://doi.org/10.1016/j.jacc.2026.09.1832","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"88 19","pages":"2198-2201"},"PeriodicalIF":22.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书